© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.
Braftovi, Mektovi and Erbitux improved outcomes for those with advanced colorectal cancer with BRAF mutation.
The novel immune-enhancing antibody delays disease progression, especially in people with a common genetic variant.
Targeted therapy combination reduced the risk of disease progression or death by 65% in a randomized study.
First nuclear export inhibitor gets the nod for patients lacking treatment options.
Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.
Together, these trials indicate that triple combos show promise and while there are significant toxicities, they are mostly manageable.
Lynparza maintenance therapy after chemotherapy nearly doubled progression-free survival.
More than 40% of people treated with enfortumab vedotin experienced complete or partial remission.
Antibody-drug conjugate carries a chemotherapy drug directly to cancerous B cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
